Clinical Pharmacokinetics

, Volume 43, Issue 14, pp 1025–1035 | Cite as

Pharmacokinetics of Quetiapine in Elderly Patients with Selected Psychotic Disorders

  • George E. Jaskiw
  • Per T. Thyrum
  • Matthew A. Fuller
  • Lisa A. Arvanitis
  • Chiao Yeh
Original Research Article



To assess the pharmacokinetics and tolerability of quetiapine in elderly patients with selected psychotic disorders.

Study design

This was a multicentre, open-label, 27-day, rising multiple-dose trial. Descriptive statistics summarised plasma quetiapine concentrations and pharmacokinetic parameters by trial day. A two-way analysis of variance was used to evaluate all pharmacokinetic parameters, and 90% confidence intervals of the mean differences were calculated.


Antipsychotic drugs taken prior to the study period were discontinued on day 1. Quetiapine treatment began on day 3. Doses were increased stepwise, starting at 25mg three times daily and reaching 250mg three times daily by day 21. Patients: Twelve patients (age 63–85 years) with schizophrenia, schizoaffective disorder or bipolar disorder.

Main outcome measures and results

Key assessments included quetiapine plasma concentrations, and neurological and safety evaluations. Under steady-state conditions, the 100 and 250mg doses of quetiapine were not significantly different in terms of dose-normalised area under the plasma concentration-time curve within an 8-hour dose administration interval, or in dose-normalised minimum plasma concentration (Cmin) at the end of a dose administration interval. The morning Cmin values for the seven discrete dose amounts evaluated also increased linearly with dose. The apparent oral clearance, volume of distribution and half-life did not change as a function of dose. There were no serious adverse events. The most common adverse events were postural hypotension (n = 6), dizziness (n = 5) and somnolence (n = 4).


While quetiapine was well tolerated at doses up to 250mg three times daily, the potential for reduced clearance, as well as the adverse effects of postural hypotension and dizziness, indicated that quetiapine should be introduced at lower doses and titrated at a relatively slower rate in patients ≥65 years.


  1. 1.
    Seroquel (quetiapine fumarate): full prescribing information. Wilmington (DE): AstraZeneca, 2004Google Scholar
  2. 2.
    Goldstein J, Arvanitis L. ICI 204,636 (seroquel), a dibenzothiazepine atypical antipsychotic: review of preclinical pharmacology and highlights of phase II clinical trials. CNS Drug Rev 1995; 1: 50–73CrossRefGoogle Scholar
  3. 3.
    Goldstein J. Pre-clinical pharmacology of new atypical antipsychotics in late stage development. Expert Opin Investig Drugs 1995; 4: 291–8CrossRefGoogle Scholar
  4. 4.
    DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet 2001; 40(7): 509–22CrossRefPubMedGoogle Scholar
  5. 5.
    Gunasekara N, Spencer C. Quetiapine a review of its use in schizophrenia. CNS Drugs 1998 Apr; 9(4): 326–40CrossRefGoogle Scholar
  6. 6.
    Grimm S, Stams K, Bui K. In vitro prediction of potential metabolic drug interactions for seroquel [abstract]. Schizophr Res 1997; 24: 200CrossRefGoogle Scholar
  7. 7.
    Thyrum PT, Wong YW, Yeh C. Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment. Prog Neuropsychopharmacol Biol Psychiatry 2000; 24(4): 521–33CrossRefPubMedGoogle Scholar
  8. 8.
    Goldner EM, Hsu L, Waraich P, et al. Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature. Can J Psychiatry 2002; 47(9): 833–43CrossRefPubMedGoogle Scholar
  9. 9.
    US Bureau of Census. International data base [online]. Washington, DC. Available from URL: http://www/idbprint.html [Accessed 2004 Aug 23]
  10. 10.
    Tsujimoto G, Hashimoto K, Hoffman BB. Pharmacokinetic and pharmacodynamic principles of drug therapy in old age (Pt 1). Int J Clin Pharmacol Ther Toxicol 1989; 27(1): 13–26PubMedGoogle Scholar
  11. 11.
    Gregory C, McKenna P. Pharmacological management of schizophrenia in older patients. Drugs Aging 1994; 5(4): 254–62CrossRefPubMedGoogle Scholar
  12. 12.
    Wilson JA, MacLennan WJ. Review: drug-induced parkinsonism in elderly patients. Age Ageing 1989; 18(3): 208–10CrossRefPubMedGoogle Scholar
  13. 13.
    Kane J, Woerner M, Lieberman J. Tardive dyskinesia incidence and risk factors. J Clin Psychopharmacol 1988; 8(4 Suppl.): 52–6Google Scholar
  14. 14.
    Schmidt G, Grohmann R, Strauss A, et al. Epidemiology of toxic delirium due to psychotropic drugs in psychiatric hospitals. Compr Psychiatry 1987; 28: 242–87CrossRefPubMedGoogle Scholar
  15. 15.
    Seymour RM, Routledge PA. Important drug-drug interactions in the elderly. Drugs Aging 1998; 12(6): 485–94CrossRefPubMedGoogle Scholar
  16. 16.
    Fabre Jr LF, Arvanitis L, Pultz J, et al. ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia. Clin Ther 1995; 17(3): 366–78CrossRefPubMedGoogle Scholar
  17. 17.
    Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebocontrolled trial in patients with schizophrenia. US SERO-QUEL Study Group. J Clin Psychopharmacol 1996; 16(2): 158–69CrossRefPubMedGoogle Scholar
  18. 18.
    Arvanitis LA, Miller BG. Multiple fixed doses of “seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997; 42(4): 233–46CrossRefPubMedGoogle Scholar
  19. 19.
    Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 1997; 54(6): 549–57CrossRefPubMedGoogle Scholar
  20. 20.
    Peuskens J, Link CG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997; 96(4): 265–73CrossRefPubMedGoogle Scholar
  21. 21.
    Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther 2001; 23(11): 1839–54CrossRefPubMedGoogle Scholar
  22. 22.
    Kasper S, Muller-Spahn F. Review of quetiapine and its clinical applications in schizophrenia. Expert Opin Pharmacother 2000; 1(4): 783–801CrossRefPubMedGoogle Scholar
  23. 23.
    Caligiuri MR, Jeste DV, Lacro JP. Antipsychotic-induced movement disorders in the elderly: epidemiology and treatment recommendations. Drugs Aging 2000; 17(5): 363–84CrossRefPubMedGoogle Scholar
  24. 24.
    Thompson II TL, Moran MG, Nies AS. Psychotropic drug use in the elderly (Pt II). N Engl J Med 1983; 308(4): 194–9CrossRefPubMedGoogle Scholar
  25. 25.
    Diagnostic and statistical manual of mental disorders. 3rd ed. rev. Washington, DC: American Psychiatric Press, 1987Google Scholar
  26. 26.
    Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12(3): 189–98CrossRefPubMedGoogle Scholar
  27. 27.
    Davis PC, Wong J, Gefvert O. Analysis and pharmacokinetics of quetiapine and two metabolites in human plasma using reversed-phase HPLC with ultraviolet and electrochemical detection. J Pharm Biomed Anal 1999; 20(1–2): 271–82CrossRefPubMedGoogle Scholar
  28. 28.
    Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212: 11–9CrossRefPubMedGoogle Scholar
  29. 29.
    Guy W, editor. AIMS: ECDEU assessment manual for psychopharmacology. Rev. ed. Rockville (MD): US Department of Health, Education, and Welfare, 1976Google Scholar
  30. 30.
    Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962; 10: 799–812CrossRefGoogle Scholar
  31. 31.
    CGI Clinical Global Impression. ECDEU assessment manual for psychopharmacology. Rev. ed. Rockville (MD): US Department of Health, Education, and Welfare, 1976Google Scholar
  32. 32.
    Andreasen N. Modified scale for the assessment of negative symptoms: NIMH treatment strategies in schizophrenia study. Washington, DC: Public Health Administration, US Department of Health and Human Services, 1984. Publication no. ADM 9-102Google Scholar
  33. 33.
    Tariot PN, Salzman C, Yeung PP, et al. Long-term use of quetiapine in elderly patients with psychotic disorders. Clin Ther 2000; 22(9): 1068–84CrossRefPubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  • George E. Jaskiw
    • 1
    • 2
  • Per T. Thyrum
    • 3
  • Matthew A. Fuller
    • 1
    • 2
  • Lisa A. Arvanitis
    • 3
  • Chiao Yeh
    • 3
  1. 1.Louis Stokes Cleveland VAMCBrecksvilleUSA
  2. 2.Department of PsychiatryCase Western Reserve UniversityClevelandUSA
  3. 3.AstraZeneca PharmaceuticalsWilmingtonUSA
  4. 4.Psychiatry Service 116A(B)Louis Stokes Cleveland VAMCBrecksvilleUSA

Personalised recommendations